# Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

> **NCT04983030** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Boris Juelg, MD PhD** · enrollment: 36 (estimated)

## Conditions studied

- HIV
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndrome, Acquired
- Sexually Transmitted Diseases, Viral
- Retroviridae Infections

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV
- **BIOLOGICAL:** MVA-BN-HIV
- **BIOLOGICAL:** PGT121
- **BIOLOGICAL:** PGDM1400
- **BIOLOGICAL:** VRC07-523LS

## Key facts

- **NCT ID:** NCT04983030
- **Lead sponsor:** Boris Juelg, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-04-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983030, "Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04983030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*